Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | PPIA | P62937 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.58 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415350 | 0.89 | HTT (0.75) | HTTTSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23796824 | 0.88 | MEN1 (0.60) | HTTPPIATSHRMEN1KMT2A | |
| SCHEMBL27898281 | 0.88 | L3MBTL1 (0.66) | HTTTSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1097553 | 0.87 | PPIA (0.56) | HTTPPIATSHRMEN1KMT2A | |
| SCHEMBL9574717 | 0.87 | HTT (0.73) | HTTTSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22438915 | 0.85 | MEN1 (0.65) | HTTPPIAMEN1KMT2AL3MBTL1 | |
| Bicarbonate SCHEMBL5184189 | 0.85 | TSHR (0.67) | HTTTSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL536025 | 0.85 | TSHR (0.71) | TSHRMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL1488776 | 0.84 | MEN1 (0.63) | HTTPPIAMEN1KMT2AL3MBTL1 | |
| SCHEMBL28877494 | 0.84 | MEN1 (0.54) | HTTPPIATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| EP-2593435-B1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | TAIRX INC (TW) | 2016-09-07 | — | — | EP | disclosed |
| CN-103347859-B | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MANAGEMENT CORP. (CN) | 2015-12-02 | — | — | CN | disclosed |
| CN-103347859-A | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MAN CORP | 2013-10-09 | — | — | CN | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
| EP-0086472-B1 | CATALYST FOR THE POLYMERIZATION OF OLEFINS | Montedison S.p.A. (IT) | 1987-05-20 | — | — | EP | disclosed |
| EP-0086472-A2 | Catalyst for the polymerization of olefins | Montedison S.p.A. (IT) | 1983-08-24 | — | — | EP | disclosed |
| US-4098816-A | HYPOGLYCEMIC AGENTS AND ANTILIPEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | HTT 3143/4885PPIA 2495/4885TSHR 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.